Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.56 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.49 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.48 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.48 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21644966 | 1.00 | KMT2A (0.59) | KMT2ASMN1; SMN2FFAR1SPHK1SPHK2 | |
| SCHEMBL29454542 | 0.90 | FFAR1 (0.66) | KMT2ASMN1; SMN2FFAR1FFAR2 | |
| SCHEMBL21644908 | 0.90 | FFAR1 (0.66) | KMT2ASMN1; SMN2FFAR1FFAR2 | |
| SCHEMBL20103403 | 0.90 | FFAR1 (0.66) | KMT2ASMN1; SMN2FFAR1FFAR2 | |
| SCHEMBL29454681 | 0.88 | KMT2A (0.56) | KMT2ASMN1; SMN2FFAR1FFAR2NR4A2 | |
| SCHEMBL21644935 | 0.86 | FFAR1 (0.59) | KMT2ASMN1; SMN2FFAR1FFAR2ALOX5 | |
| SCHEMBL29454565 | 0.86 | FFAR1 (0.59) | KMT2ASMN1; SMN2FFAR1FFAR2ALOX5 | |
| SCHEMBL20103667 | 0.86 | FFAR1 (0.59) | KMT2ASMN1; SMN2FFAR1FFAR2ALOX5 | |
| SCHEMBL30211110 | 0.84 | FFAR1 (0.53) | KMT2ASMN1; SMN2FFAR1SPHK1SPHK2 | |
| SCHEMBL22717572 | 0.84 | FFAR1 (0.53) | KMT2ASMN1; SMN2FFAR1SPHK1SPHK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-27 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2020-02-06 | — | — | US | disclosed |
| WO-2018081047-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200039914-A1 | CYCLOHEXYL GPR40 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES | GPR119, GPR65, GPR55 | KMT2A 3114/4885SMN1; SMN2 4068/4885FFAR1 16/4885 |
| US-10988433-B2 | Cyclohexyl GPR40 agonists for the treatment of type II diabetes | GPR119, GPR65, GPR55 | KMT2A 3114/4885SMN1; SMN2 4068/4885FFAR1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.